Novacea Gains Worldwide Rights To Phase I Cancer Compound From KuDOS
This article was originally published in The Pink Sheet Daily
Firm announces agreement with AstraZeneca subsidiary to develop and commercialize banoxantrone, for which it already had North American rights.
You may also be interested in...
Novacea emphasizes collaborative nature of the agreement, pointing to pre-commercial milestones and larger-than-usual royalties on sales.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.